Canadian group Izotropic has chosen Morocco to deploy its cutting-edge imaging technology in breast cancer detection, which will enable the Kingdom to become a regional leader and launch-pad for its operations in Africa and the Gulf region.
The Canadian group has set up a subsidiary based in Casablanca. The new entity, “Izotropic Africa”, has entered into partnership discussions with the Mohammed VI Foundation for Science & Health (FM6SS).
Izotropic Africa is tasked with licensing, marketing, and distribution of the Company’s proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
A press release issued by the Canadian group says the partnership discussions between Izotropic Africa and the FM6SS focus on clinical research, regulatory advancement, and manufacturing and assembly opportunities in Morocco for the Company’s proprietary medical device, the IzoView Breast CT Imaging System.
As part of these discussions, an IzoView device valued at USD $500K would be placed at a leading hospital in Morocco at no cost as a clinical research site to support local clinical evaluation and regulatory approvals.
The discussions also include the evaluation of opportunities for localized manufacturing and assembly initiatives in Morocco, with the kingdom’s geographic position at the intersection of Europe, Africa, and the Middle East providing access to regional markets with established logistics channels.
Morocco is seeking to strengthen domestic medical device manufacturing, expand access to advanced healthcare technologies, and build long-term research and development capacity.
The Kingdom is also working to reinforce supply-chain resilience, promote “Made in Morocco” manufacturing, support industrial investment, and align workforce development with sector growth.
